

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/216200 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) *A61K 45/06* (2006.01)
A61K 31/555 (2006.01) *A61K 9/00* (2006.01)
A61K 31/573 (2006.01) *A61P 35/00* (2006.01)
A61K 31/714 (2006.01) *A61P 35/04* (2006.01)

(21) International Application Number:

PCT/US2024/024485

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/459,349 14 April 2023 (14.04.2023) US
63/520,050 16 August 2023 (16.08.2023) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **MEHTA, Bhakti**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **HENARY, Haby**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **NGARMCHAMNANRITH, Gataree**; c/o Amgen Inc., One Amgen Center Drive, Legal Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **RYBKIN, Igor Ivanovich**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **PARK, Joseph**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **BERGAUER, Markus**; Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

WO 2024/216200 A1

(54) Title: DOSAGE REGIMEN FOR SOTORASIB/CARBOPLATIN/PEMETREXED IN CANCER TREATMENT

(57) Abstract: Provided herein are methods of treating cancer comprising a *KRAS G12C* mutation in a subject in need thereof comprising administering to the subject sotorasib, carboplatin and pemetrexed in amounts effective to treat the cancer.